Aldeyra enrolls first patient in ADX-629 trial

Aldeyra announced enrollment of the first patient in the Phase 2 clinical trial of orally administered RASP modulator ADX-629, an investigational new drug, for the treatment of atopic dermatitis. The multicenter, adaptive, two-part Phase 2 clinical trial will evaluate the safety and efficacy of ADX-629 alone and in combination with standard of care in adults with mild, moderate, or severe atopic dermatitis. In Part 1, approximately 10 patients will receive open-label ADX-629 twice daily for 90 days. Outcomes will include improvement in Investigator Global Assessment and Eczema Area and Severity Index scores. Top-line results from Part 1 are expected in the second half of 2023. Pending the results of Part 1, Part 2 will randomize patients to either ADX-629 or placebo treatment twice daily for 90 days.